Found 16 matching trials
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) PHASE2 This study is a prospective, single-arm, phase II clinical study for patien...
Show More Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Learn More & Join Trial
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer PHASE2 This study is a prospective, single-center, open-label, umbrella-shaped pha...
Show More Location
Cancer Hospital Affiliated to Fudan University
Learn More & Join Trial
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China PHASE2 The objective of this study is to evaluate the efficacy of combination of p...
Show More Learn More & Join Trial
Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant ) PHASE2 Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 an...
Show More Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Learn More & Join Trial
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy PHASE2 The purpose of this study is to determine if the triplet combination of dal...
Show More Location
Tianjin Cancer Hospital
Learn More & Join Trial
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure PHASE1 This is an open-label, single-center, exploratory, Phase Ib/II clinical tri...
Show More Location
Tianjin Medical University Cancer Institute and Hospital
Learn More & Join Trial
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive,HR-Positive Metastatic Breast Cancer PHASE2 HR+/HER2+(Human epidermal growth factor receptor 2 positive and hormone rec...
Show More Location
Sun Yat-Sen University Cancer Center
Learn More & Join Trial
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) PHASE2 Based on different HR status, we explored the efficacy and safety of Pyroti...
Show More Location
Henan Cancer Hospital
Learn More & Join Trial
Young Patients With Early Breast Cancer N/A The prognosis of young patients with breast cancer is relatively poor. Chem...
Show More Status
Active Not Recruiting
Location
Peking Union Medical College Hospital
Learn More & Join Trial
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer PHASE2 This is a prospective Single-arm Study to Investigate the Efficacy and Safe...
Show More Location
Fudan University Shanghai Cancer Hospital
Learn More & Join Trial